<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614116</url>
  </required_header>
  <id_info>
    <org_study_id>Cold exposure of WAT</org_study_id>
    <nct_id>NCT04614116</nct_id>
  </id_info>
  <brief_title>Cold Induced Futile Cycles In White Adipose Tissue</brief_title>
  <acronym>Metabol</acronym>
  <official_title>Cold Induced Futile Cycles In White Adipose Tissue: Quantification And Characterization With Dual Glucose Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Baden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Baden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of futile cycles in white adipose tissue under cold conditions for&#xD;
      thermogenesis using two substitutes for glucose metabolism (18F-FDG and 13C-Glucose).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thermogenesis is defined as a process, which generates heat by the depletion of energy-rich&#xD;
      molecules. Evolutionary, it is an essential process that allows the survival at lower&#xD;
      temperatures. Since the discovery of brown adipose tissue (BAT) it is believed that this part&#xD;
      of the adipose tissue can dissipate energy for heat thanks to the uncoupling protein 1&#xD;
      (UCP1). Since energy expenditure is increased as a consequence of thermogenesis,&#xD;
      pharmacological induction of this pathway presents an interesting therapeutic target to&#xD;
      counter obesity. However, recent investigations indicate that white adipose tissue (WAT) is&#xD;
      much more versatile and probably essentially indispensable for thermogenesis.&#xD;
&#xD;
      To investigate the mechanism of this futile cycle in WAT we plan to investigate the glucose&#xD;
      metabolism in 24 healthy volunteers with 2 exams (one with and one without external cooling)&#xD;
      with two substitutes for glucose. We will use 18F-FDG to quantify the glucose influx into WAT&#xD;
      using dynamic PET/CT scans and 13C-Glucose to analyze the downstream metabolites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non blinded, randomised, open label</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of FDG influx into WAT</measure>
    <time_frame>2 days</time_frame>
    <description>Comparing the 18F-FDG influx rate (Ki) into the white adipose tissue with and without cold stimulation (intra-individually).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of 13C-Glucose metabolites in fat</measure>
    <time_frame>2 days</time_frame>
    <description>Comparing the 13C-Glucose accumulation in white adipose tissue between Group A (without cold) and B (with cold) stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of 13C-Glucose metabolites in blood</measure>
    <time_frame>2 days</time_frame>
    <description>13C-Lactate concentration in blood samples between Group A (without cold) and B (with cold) stimulation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metabolism Disorder</condition>
  <arm_group>
    <arm_group_label>Biopsy without cold induction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will undergo a fat biopsy after the first scan, without cooling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biopsy with cold induction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will undergo a fat biopsy after the second scan, with cooling</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>External cooling</intervention_name>
    <description>water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.</description>
    <arm_group_label>Biopsy with cold induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDG PET/CT</intervention_name>
    <description>o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.</description>
    <arm_group_label>Biopsy with cold induction</arm_group_label>
    <arm_group_label>Biopsy without cold induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>13C-Glucose injection</intervention_name>
    <description>0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection</description>
    <arm_group_label>Biopsy with cold induction</arm_group_label>
    <arm_group_label>Biopsy without cold induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  Healthy participants, as determined by screening assessments and Principal&#xD;
             Investigator's judgment&#xD;
&#xD;
          -  Health status is defined by the absence of evidence of any active or chronic disease&#xD;
             following a medical and surgical history, basic physical examination and blood test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any clinically relevant history or the presence of e.g. respiratory, renal, hepatic,&#xD;
             gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             metabolic disease, etc.&#xD;
&#xD;
          -  Intake of the following medications: Insulin, oral antidiabetic drugs, GLP-1-agonists,&#xD;
             Corticosteroids, Sympathomimetic and Sympatholytic drug, Beta-Blocker, Statins.&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Resting pulse rate &gt; 70 bpm, resting blood pressure &gt; 130/90 mmHg.&#xD;
&#xD;
          -  Serum creatinine &gt; 145 µmol/L&#xD;
&#xD;
          -  ASAT&gt; 75 U/L and ALAT &gt; 75 U/L&#xD;
&#xD;
          -  γ GT &gt; 100 UI/L and total bilirubin &gt; 30 µmol/l&#xD;
&#xD;
          -  Glucose &gt; 7.1 mmol/L&#xD;
&#xD;
          -  HbA1c &gt; 46 mmol/mol (&gt;6.4%)&#xD;
&#xD;
          -  Intake of anticoagulants or inhibitors of platelet aggregation (e.g. Aspirin,&#xD;
             clopidogrel).&#xD;
&#xD;
          -  Known tendency to form keloids (hypertrophic scar tissue)&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse,&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant,&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study&#xD;
&#xD;
          -  Participation in another study involving ionizing radiation in the same year&#xD;
&#xD;
          -  Previous enrolment into the current study,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only male volunteers</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene A. Burger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Baden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene A Burger, MD</last_name>
    <phone>056 486 38 71</phone>
    <phone_ext>+41</phone_ext>
    <email>irene.burger@ksb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riccardo Laudicella, MD</last_name>
    <phone>056 486 38 80</phone>
    <phone_ext>+41</phone_ext>
    <email>riccardo.laudicella@ksb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspitla Baden</name>
      <address>
        <city>Baden</city>
        <state>Aargau</state>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene A Burger</last_name>
      <phone>+41564863871</phone>
      <email>irene.burger@ksb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Ladwig</last_name>
      <phone>+41564863873</phone>
      <email>claudia.ladwig@ksb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Baden</investigator_affiliation>
    <investigator_full_name>Irene A. Burger</investigator_full_name>
    <investigator_title>Head of clinic</investigator_title>
  </responsible_party>
  <keyword>Glucose metablism</keyword>
  <keyword>futil cycles</keyword>
  <keyword>FDG PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

